Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free AGPU Stock Alerts

Predictive Oncology (AGPU) Competitors

Predictive Oncology logo
$7.08 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$7.15 +0.07 (+0.99%)
As of 07/2/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AGPU vs. SGHT, CNXU, TMCI, TLSI, and OBIO

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include Sight Sciences (SGHT), Conexeu Sciences (CNXU), Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to Sight Sciences?

Predictive Oncology (NASDAQ:AGPU) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, Predictive Oncology and Predictive Oncology both had 1 articles in the media. Predictive Oncology's average media sentiment score of 0.00 equaled Sight Sciences'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sight Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 30.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Predictive Oncology has a beta of 3.43, indicating that its share price is 243% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Sight Sciences has a consensus price target of $8.14, indicating a potential upside of 49.43%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Sight Sciences has higher revenue and earnings than Predictive Oncology. Sight Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$50.29K1,523.29-$233.10M-$8.18N/A
Sight Sciences$77.36M3.83-$38.43M-$0.71N/A

Sight Sciences has a net margin of -46.83% compared to Predictive Oncology's net margin of -470,383.31%. Sight Sciences' return on equity of -52.34% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-470,383.31% -7,363.67% -626.32%
Sight Sciences -46.83%-52.34%-28.49%

Summary

Sight Sciences beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and Predictive Oncology (NASDAQ:AGPU) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Conexeu Sciences has higher earnings, but lower revenue than Predictive Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/AN/AN/AN/A
Predictive Oncology$50.29K1,523.29-$233.10M-$8.18N/A

Conexeu Sciences presently has a consensus price target of $20.00, indicating a potential upside of 84.16%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Conexeu Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Conexeu Sciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -470,383.31%. Conexeu Sciences' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
Predictive Oncology -470,383.31%-7,363.67%-626.32%

In the previous week, Conexeu Sciences had 12 more articles in the media than Predictive Oncology. MarketBeat recorded 13 mentions for Conexeu Sciences and 1 mentions for Predictive Oncology. Conexeu Sciences' average media sentiment score of 0.92 beat Predictive Oncology's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Conexeu Sciences beats Predictive Oncology on 8 of the 11 factors compared between the two stocks.

How does Predictive Oncology compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Treace Medical Concepts presently has a consensus target price of $4.77, indicating a potential upside of 13.30%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, equities analysts clearly believe Treace Medical Concepts is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 1 articles in the media. Treace Medical Concepts' average media sentiment score of 0.59 beat Predictive Oncology's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Treace Medical Concepts has a net margin of -29.44% compared to Predictive Oncology's net margin of -470,383.31%. Treace Medical Concepts' return on equity of -67.04% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-29.44% -67.04% -30.28%
Predictive Oncology -470,383.31%-7,363.67%-626.32%

Treace Medical Concepts has higher revenue and earnings than Predictive Oncology. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M1.28-$59M-$0.97N/A
Predictive Oncology$50.29K1,523.29-$233.10M-$8.18N/A

Treace Medical Concepts has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.43, meaning that its stock price is 243% more volatile than the broader market.

Summary

Treace Medical Concepts beats Predictive Oncology on 12 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 1 articles in the media. TriSalus Life Sciences' average media sentiment score of 1.67 beat Predictive Oncology's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TriSalus Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TriSalus Life Sciences has a net margin of -60.85% compared to Predictive Oncology's net margin of -470,383.31%. TriSalus Life Sciences' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-60.85% N/A -69.91%
Predictive Oncology -470,383.31%-7,363.67%-626.32%

TriSalus Life Sciences has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.43, indicating that its share price is 243% more volatile than the broader market.

TriSalus Life Sciences presently has a consensus price target of $7.50, indicating a potential upside of 59.91%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe TriSalus Life Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TriSalus Life Sciences has higher revenue and earnings than Predictive Oncology. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M6.38-$39.23M-$1.41N/A
Predictive Oncology$50.29K1,523.29-$233.10M-$8.18N/A

Summary

TriSalus Life Sciences beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Orchestra BioMed and Orchestra BioMed both had 1 articles in the media. Orchestra BioMed's average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orchestra BioMed
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Orchestra BioMed has higher revenue and earnings than Predictive Oncology. Orchestra BioMed is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchestra BioMed$33.48M7.49-$52.70M-$0.97N/A
Predictive Oncology$50.29K1,523.29-$233.10M-$8.18N/A

Orchestra BioMed has a net margin of -166.96% compared to Predictive Oncology's net margin of -470,383.31%. Orchestra BioMed's return on equity of -157.46% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Orchestra BioMed-166.96% -157.46% -60.18%
Predictive Oncology -470,383.31%-7,363.67%-626.32%

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Orchestra BioMed has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.43, suggesting that its stock price is 243% more volatile than the broader market.

Orchestra BioMed currently has a consensus target price of $13.60, indicating a potential upside of 224.58%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchestra BioMed
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Orchestra BioMed beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGPU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGPU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGPU vs. The Competition

Export
MetricPredictive OncologySurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$76.60M$3.23B$5.20B$12.48B
Dividend YieldN/AN/A16.11%6.52%
P/E Ratio-0.8720.0723.9124.70
Price / Sales1,523.29389.38216.8399.49
Price / CashN/A9.2735.0657.09
Price / Book0.615.7913.256.46
Net Income-$233.10M$7.39M$113.80M$337.01M
7 Day Performance-1.12%0.70%0.93%1.69%
1 Month Performance-8.41%-0.17%1.08%3.81%
1 Year PerformanceN/A-38.62%10.03%23.90%

Predictive Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGPU
Predictive Oncology
0.3741 of 5 stars		$7.08
flat		N/AN/A$76.60M$50.29KN/A30
SGHT
Sight Sciences
2.8878 of 5 stars		$5.44
+0.4%		$8.14
+49.7%		+29.0%$295.99M$77.36MN/A210
CNXU
Conexeu Sciences
4.654 of 5 stars		$10.26
-6.0%		$20.00
+94.9%		N/A$274.54MN/AN/A4
TMCI
Treace Medical Concepts
2.1858 of 5 stars		$4.23
+6.3%		$4.77
+12.8%		-30.4%$274.40M$212.69MN/A250
TLSI
TriSalus Life Sciences
3.5319 of 5 stars		$4.46
-2.0%		$7.50
+68.2%		-8.4%$273.93M$45.15MN/A106

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AGPU) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel